JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review

Publication date: Available online 16 January 2020Source: Leukemia Research ReportsAuthor(s): Toshie Ogasawara, Kiyotaka Kawauchi, Takuya Ono, Kotaro Shide, Kazuya Shimoda, Naoki Mori, Hiroshi SakuraAbstractEssential thrombocythemia (ET) is an indolent myeloproliferative neoplasm (MPN) with a transformation to acute myeloid leukemia in
Source: Leukemia Research Reports - Category: Hematology Source Type: research

Related Links:

T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Because expression of the aberrant target protein is exclusive to malignant cells, immunotherapy directed against neoantigens should avoid “on-target, off-tumor” toxicity. The efficacy of neoantigen vaccines in melanoma and glioblastoma and of adoptive transfer of neoantigen-specific T cells in epithelial tumors indicates that neoantigens are valid therapeutic targets. Improvements in sequencing tec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 7 February 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Stephan Bartels, Britta Hasemeier, Julia Vogtmann, Elisa Schipper, Guntram Büsche, Jerome Schlue, Hans Kreipe, Ulrich LehmannAbstractChromosomal translocations resulting in fusion genes represent important oncogenic drivers and potential therapeutic targets in rare leukemia subtypes. Formalin-fixed and paraffin-embedded trephines are frequently used in hematologic diagnostic and provide relevant access to leukemic cells for further studies, e.g. phenotyping in bone marrow fibrosis. However, high-throughput molecula...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
In conclusion, the OMR panel is a highly accurate and reproducible next-generation sequencing panel for the detection of common genetic alterations in myeloid neoplasms.
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
We analyzed the clinical characteristics, laboratory characteristics, cytogenetics, thromboembolism status, disease progression, and overall survival of 1537 Chinese MPN patients with the JAK2V617F mutation. The multivariate analysis indicated that age ≥60 years old, HCT ≥48%, at least one cardiovascular risk factor, history of thrombosis, and JAK2V617F allele burden (V617F%) ≥50% are risk factors for thrombosis of JAK2V617F‐mutated MPN. Our study suggested that for elderly patients with JAK2V617F‐mutated MPN and a history of thrombosis, reducingV617F%, controlling HCT, and mitigating cardiovascular risk ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Journal of Medicinal ChemistryDOI: 10.1021/acs.jmedchem.0c00025
Source: Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research
We previously demonstrated poor outcomes of patients with acute myeloid leukemia (AML) with antecedent myeloproliferative neoplasms (MPN) undergoing allogeneic hematopoietic stem cell transplantation (HCT) (Gupta et al, BBMT, 2019; abstract 140). In particular, we did not find any difference in outcomes of patients who received transplant “in remission” defined as blood and bone marrow blasts
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 12 Source Type: research
The WHO 2016 AML-MRC designation applies to AML patients (pts) with a history of myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm, a MDS-related cytogenetic abnormality, or multilineage dysplasia in>50% of ≥2 cell lineages in the absence of NPM1 or biallelic CEBPA mutations. AML-MRC pts typically have a poor prognosis after induction chemotherapy. CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D] at a sy nergistic ratio, is approved by the FDA and EMA for the treatment of adults with newly diagnosed th...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 9 Source Type: research
Relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) following an allogeneic stem cell transplant has a bleak prognosis with no standard for treatment identified. Current literature suggests combining hypomethylating agents (HMA) with a donor lymphocyte infusion (DLI) as salvage therapy to reduce disease burden and induce a graft versus leukemia (GVL) effect. At our institution, this salvage therapy option is being used for this population, peaking interest in our experience to date.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 608 Source Type: research
We present a retrospective analysis of several reduced intensity conditioning (RIC) regimens. Methods This was a retrospective study with an aim of comparing survival outcomes in patients with myeloid disorders [acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic disorders (MDS), and myeloproliferative neoplasms (MPN)] who underwent HCT at our institution between the years 2008-2017.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 235 Source Type: research
Modern Pathology, Published online: 02 January 2020; doi:10.1038/s41379-019-0447-xDetection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis
Source: Modern Pathology - Category: Pathology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Myeloproliferative Disorders